Market news: Novo Nordisk announced the latest developments in the ZEUS phase III clinical trial, which targets patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation.

Zhitongcaijing · 3d ago
Market news: Novo Nordisk announced the latest developments in the ZEUS phase III clinical trial, which targets patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation.